Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Rises By 5.3%

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) saw a significant growth in short interest in October. As of October 15th, there was short interest totalling 4,610,000 shares, a growth of 5.3% from the September 30th total of 4,380,000 shares. Based on an average trading volume of 459,900 shares, the short-interest ratio is currently 10.0 days. Currently, 12.3% of the shares of the company are short sold.

Checkpoint Therapeutics Stock Up 1.5 %

CKPT traded up $0.05 on Friday, hitting $3.49. 154,038 shares of the company traded hands, compared to its average volume of 507,684. The company has a 50 day moving average of $2.53 and a 200-day moving average of $2.18. Checkpoint Therapeutics has a 12-month low of $1.36 and a 12-month high of $3.97. The stock has a market capitalization of $157.12 million, a PE ratio of -1.81 and a beta of 1.30.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.11. The company had revenue of $0.04 million for the quarter. On average, research analysts anticipate that Checkpoint Therapeutics will post -0.81 EPS for the current year.

Institutional Trading of Checkpoint Therapeutics

Several hedge funds have recently made changes to their positions in CKPT. Choreo LLC raised its stake in shares of Checkpoint Therapeutics by 200.9% during the 1st quarter. Choreo LLC now owns 57,922 shares of the company’s stock worth $119,000 after buying an additional 38,672 shares in the last quarter. Vanguard Group Inc. grew its holdings in Checkpoint Therapeutics by 67.4% during the 1st quarter. Vanguard Group Inc. now owns 917,894 shares of the company’s stock valued at $1,882,000 after buying an additional 369,586 shares during the last quarter. 180 Wealth Advisors LLC purchased a new position in Checkpoint Therapeutics during the second quarter worth $96,000. XTX Topco Ltd acquired a new position in shares of Checkpoint Therapeutics in the second quarter worth $34,000. Finally, B. Riley Wealth Advisors Inc. lifted its position in shares of Checkpoint Therapeutics by 366.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock valued at $493,000 after acquiring an additional 180,050 shares in the last quarter. Institutional investors and hedge funds own 22.00% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Checkpoint Therapeutics in a report on Monday, September 16th.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.